← Back to headlines
Praxis Precision Stock Rises on FDA Review Acceptance
Praxis Precision Medicine's stock saw gains after its lead asset was accepted for review by the U.S. Food and Drug Administration.
14 Apr, 12:18 — 14 Apr, 12:18
Sources
Showing 1 of 1 sources
Related Stories
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
3h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
5h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
9h ago
West Nile Virus Outbreaks Spread Across Greece and North Macedonia
10h ago